Results 21 to 30 of about 118,712 (218)

High-level resistance to non-nucleos(t)ide reverse transcriptase inhibitor based first-line antiretroviral therapy in Ghana; A 2017 study

Frontiers in Microbiology, 2022
Expanding access to effective antiretroviral therapy (ART) is a major tool for management of Human Immunodeficiency Virus (HIV) infection. However, rising levels of HIV drug-resistance have significantly hampered the anticipated success of ART in persons
Prince Kofi Parbie, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Christopher Zaab-Yen Abana, Dennis Kushitor, Theodore Worlanyo Asigbee, Theodore Worlanyo Asigbee, Nana Afia Asante Ntim, Nana Afia Asante Ntim, Gifty Addo-Tetebo, Maclean Richard Darko Ansong, Sampson Badu Ofori, Taketoshi Mizutani, Lucky Ronald Runtuwene, Masako Nishizawa, Koichi Ishikawa, Hiroshi Kiyono, Hiroshi Kiyono, Hiroshi Kiyono, William Kwabena Ampofo, Tetsuro Matano, Tetsuro Matano, Tetsuro Matano, Evelyn Yayra Bonney, Tadashi Kikuchi   +24 more
doaj   +1 more source

Natural Plant Alkaloid (Emetine) Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity

Molecules, 2015
Ipecac alkaloids are secondary metabolites produced in the medicinal plant Psychotria ipecacuanha. Emetine is the main alkaloid of ipecac and one of the active compounds in syrup of Ipecac with emetic property. Here we evaluated emetine’s potential as an
Ana Luiza Chaves Valadão, Celina Monteiro Abreu, Juliana Zanatta Dias, Pablo Arantes, Hugo Verli, Amilcar Tanuri, Renato Santana de Aguiar   +6 more
doaj   +1 more source

Discovery of diarylpyrimidine derivatives bearing piperazine sulfonyl as potent HIV-1 nonnucleoside reverse transcriptase inhibitors

Communications Chemistry, 2023
HIV-1 reverse transcriptase is one of the most attractive targets for the treatment of AIDS. However, the rapid emergence of drug-resistant strains and unsatisfactory drug-like properties seriously limit the clinical application of HIV-1 non-nucleoside ...
Xiangyi Jiang, Boshi Huang, Shawn Rumrill, David Pople, Waleed A. Zalloum, Dongwei Kang, Fabao Zhao, Xiangkai Ji, Zhen Gao, Lide Hu, Zhao Wang, Minghui Xie, Erik De Clercq, Francesc X. Ruiz, Eddy Arnold, Christophe Pannecouque, Xinyong Liu, Peng Zhan   +17 more
doaj   +1 more source

HuR interacts with human immunodeficiency virus type 1 reverse transcriptase, and modulates reverse transcription in infected cells [PDF]

, 2008
Reverse transcription of the genetic material of human immunodeficiency virus type 1 (HIV-1) is a critical step in the replication cycle of this virus. This process, catalyzed by reverse transcriptase (RT), is well characterized at the biochemical level.
Julie Lemay, Priscilla Maidou-Peindara, Thomas Bader, Eric Ennifar, Jean-Christophe Rain, Richard Benarous, Lang Liu   +6 more
core   +2 more sources

Nucleoside reverse transcriptase inhibitors and HIV mutagenesis [PDF]

Journal of Antimicrobial Chemotherapy, 2003
Potent antiretroviral therapy (ART) of HIV-1 infection with anti-retroviral drugs consisting of nucleoside reverse transcriptase inhibitors(NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs)and protease inhibitors (PIs) has dramatically reduced the rate ofHIV- and AIDS-related morbidity and mortality. The lack of patientcompliance to drug
Nancy A, Jewell, Renxiang, Chen, Raquel, Raices, Louis M, Mansky   +3 more
openaire   +2 more sources

Optimization of diarylazines as anti-HIV agents with dramatically [PDF]

, 2013
Non-nucleoside inhibitors of HIV-1 reverse transcriptase are reported that have ca. 100-fold greater solubility than the structurally related drugs etravirine and rilpivirine, while retaining high anti-viral activity.
Anderson, Karen S., Bollini, Mariela, Cisneros, José A., Jorgensen, William L., Spasov, Krasimir A.   +4 more
core   +1 more source

HIV Drug Resistance Mutations in Patients with HIV and HIV-TB Coinfection After Failure of First-Line Therapy: A Prevalence Study in a Resource-Limited Setting

Journal of the International Association of Providers of AIDS Care, 2019
Introduction: The present study aimed to report the prevalent HIV-1 drug-resistant mutations in patients with HIV-1 alone and tuberculosis (TB) coinfection alone to improve our understanding of the mutation patterns and aid treatment decisions.
Nawaid Hussain Khan PhD, Mikashmi Kohli PhD, Kartik Gupta MD, Bimal Kumar Das MD, Ravindra Mohan Pandey PhD, Sanjeev Sinha MD   +5 more
doaj   +1 more source

HIV-1 and HIV-2 Reverse Transcriptases: Different Mechanisms of Resistance to Nucleoside Reverse Transcriptase Inhibitors [PDF]

Journal of Virology, 2012
ABSTRACT As anti-HIV therapy becomes more widely available in developing nations, it is clear that drug resistance will continue to be a major problem. The related viruses HIV-1 and HIV-2 share many of the same resistance pathways to nucleoside reverse transcriptase inhibitors (NRTIs).
Paul L, Boyer, Patrick K, Clark, Stephen H, Hughes   +2 more
openaire   +2 more sources

Exploring the role of the α-carboxyphosphonate moiety in the HIV-RT activity of α-carboxy nucleoside phosphonates [PDF]

, 2016
As α-carboxy nucleoside phosphonates (α-CNPs) have demonstrated a novel mode of action of HIV-1 reverse transcriptase inhibition, structurally related derivatives were synthesized, namely the malonate 2, the unsaturated and saturated bisphosphonates 3 ...
Arnold, Eddy, Balzarini, Jan, Das, Kalyan, Ford, Alan, Maguire, Anita R., Maguire, Nuala M., Mullins, Nicholas D.   +6 more
core   +1 more source

Genetic diversity and drug resistance of HIV-1 among infected pregnant women newly diagnosed in Luanda, Angola.

PLoS ONE, 2019
Monitoring genetic diversity and drug resistance mutations (DRMs) is critical for understanding HIV epidemiology. Here, we report HIV-1 genetic diversity and DRMs in blood samples from 42 HIV-positive pregnant women naive to antiretroviral therapy (ART),
Cruz S Sebastião, Zoraima Neto, Carlos S de Jesus, Marinela Mirandela, Domingos Jandondo, José C Couto-Fernandez, Amilcar Tanuri, Joana Morais, Miguel Brito   +8 more
doaj   +1 more source